Browse the evidence

Administration of ursodeoxycholic acid (UDCA) attenuates high-fat diet-induced obesity in mice by increasing hepatic levels of non-12-hydroxylated bile acids (non-12-OH BAs), which enhances GLP-1 secretion and upregulates UCP1 and PGC1a in brown adipose tissue.

This research suggests that ursodeoxycholic acid (UDCA) may help prevent obesity in the context of a high-fat diet by boosting beneficial bile acids (non-12-OH BAs). These bile acids signal the body to burn more energy (via UCP1 in fat tissue) and release satiety hormones (GLP-1). While this is a promising therapeutic avenue, it is currently based on animal models. For humans, maintaining a healthy weight through diet and exercise remains the primary strategy, but this mechanism highlights why bile acid health is important for metabolic function.

Higher serum levels of indolepropionic acid (IPA), a gut microbiota metabolite derived from dietary tryptophan, are associated with a lower incidence of type 2 diabetes and reduced low-grade inflammation in high-risk individuals.

While you cannot directly supplement IPA effectively based on this study, the findings suggest that a diet high in fiber supports gut bacteria that produce IPA. This metabolic pathway is linked to lower inflammation and a reduced risk of type 2 diabetes. Prioritize fiber-rich whole foods to support this natural protective mechanism.

Inhibiting adipogenesis (the differentiation of preadipocytes into mature adipocytes) via modulation of transcription factors (C/EBP, PPARγ) and signaling pathways (Wnt, AMPK) is a viable therapeutic strategy for preventing or treating obesity.

This paper does not provide a direct lifestyle protocol but identifies the biological target: stopping the creation of new fat cells. For a layperson, this implies that interventions aiming to reduce obesity should focus on mechanisms that inhibit fat cell differentiation, such as those found in certain natural products or drugs targeting PPARγ or AMPK pathways, rather than just calorie restriction alone.

Natural products and conventional medications (Statins, Fibrates, Niacin) can inhibit or modulate adipogenesis through specific molecular pathways, offering potential anti-obesity effects.

Current medications like Statins and Fibrates, and various natural products, affect fat cell biology. Statins decrease lipid accumulation and increase small adipocytes. Fibrates increase fatty acid oxidation. Niacin stimulates adipogenesis markers. These mechanisms suggest that existing drugs have off-target effects on fat biology that could be leveraged.

Elevated circulating branched-chain amino acid (BCAA) levels are strongly associated with insulin resistance and type 2 diabetes, potentially acting as mediators through mTORC1 activation and accumulation of toxic metabolites like acylcarnitines and ceramides.

If you have insulin resistance or type 2 diabetes, high levels of branched-chain amino acids (found in protein) in your blood are linked to worse metabolic health. While protein is essential, simply consuming more BCAAs may not help and could potentially worsen insulin resistance in susceptible individuals. Focus on overall metabolic health and consult a provider before high-dose BCAA supplementation.

Bariatric surgery, specifically Roux-en-Y gastric bypass, reduces BCAA levels and improves insulin sensitivity, an effect not seen with weight loss alone via gastric banding.

If you undergo Roux-en-Y gastric bypass, your BCAA levels are likely to drop, which helps improve insulin sensitivity. This benefit is specific to the type of surgery and not just weight loss.

Inhibition of the host enzyme indoleamine 2,3-dioxygenase 1 (IDO1) improves metabolic health by shifting tryptophan metabolism toward gut microbiota-derived indole metabolites, which restore intestinal barrier integrity and reduce systemic inflammation.

To support metabolic health, prioritize dietary patterns that foster a diverse gut microbiome capable of converting dietary tryptophan into protective indole metabolites. This involves consuming sufficient fiber and diverse plant sources. Emerging research suggests that inhibiting the host enzyme IDO1 (which is upregulated in obesity) allows the microbiota to produce more of these beneficial indoles, thereby improving insulin sensitivity and reducing inflammation. While direct IDO1 inhibitors are not yet standard care, supporting the microbiome's ability to perform this conversion is a key mechanistic target.

Elevated serum levels of the pro-inflammatory cytokine IL-6 and the IL-6/IL-10 ratio are positively associated with the presence of sarcopenia in elderly individuals.

For older adults, high levels of systemic inflammation (specifically IL-6) are linked to muscle loss. While you cannot directly 'dose' IL-6, managing chronic inflammation through diet, exercise, and medical management of inflammatory conditions may help preserve muscle mass. The study highlights that inflammation is a key biological driver, not just a side effect.

Elevated levels of the anti-inflammatory cytokine IL-10 are also positively associated with sarcopenia in the elderly, potentially acting as a compensatory response to chronic inflammation.

High IL-10 levels in sarcopenia may indicate the body's attempt to fight inflammation. This suggests that simply boosting anti-inflammatory markers might not be enough if the underlying pro-inflammatory drive (IL-6) is too strong. Focus on reducing overall inflammatory load.

Administration of the highly proliferative probiotic strain Bifidobacterium animalis ssp. lactis GCL2505 (BlaG) ameliorates metabolic disorders, specifically improving glucose tolerance and reducing visceral fat accumulation, by modulating gut microbiota to elevate acetate levels and subsequently increasing glucagon-like peptide-1 (GLP-1) secretion.

If you are looking to use probiotics to support metabolic health, specifically glucose control and fat management, the specific strain matters significantly. This research suggests that Bifidobacterium animalis ssp. lactis GCL2505, taken daily at 1 billion CFU, may help improve glucose tolerance and reduce visceral fat in the context of a high-fat diet by increasing gut acetate and GLP-1. However, this was observed in mice, and human results may vary. It highlights that 'proliferative' strains might be more effective than non-proliferative ones for these specific outcomes.

IL-22, produced by Th22 cells, has a beneficial effect on NAFLD by alleviating steatosis and reducing transaminase levels through STAT3-mediated mechanisms, although its role in obesity pathogenesis is complex and context-dependent.

IL-22 shows promise in reducing liver fat and inflammation in NAFLD models. While not a current standalone therapy, understanding its protective role highlights the potential of targeting specific cytokine pathways for liver health. Current management focuses on weight loss and metabolic control.

Caloric restriction extends lifespan and promotes longevity by inducing dramatic changes in mitochondrial protein acetylation, thereby enhancing mitochondrial adaptation to reduced caloric intake.

Caloric restriction is a proven method to extend lifespan in various species by altering how mitochondria function. This happens through changes in protein acetylation, which helps cells adapt to lower energy availability. While strict restriction is hard to maintain, the underlying mechanism suggests that managing energy intake to avoid overfeeding may support healthy aging processes.

Aberrant protein posttranslational modifications (PTMs) are central drivers of metabolic diseases including diabetes, obesity, and atherosclerosis, and targeting these modifications offers a viable therapeutic strategy.

Metabolic diseases are driven by complex molecular switches (PTMs) that regulate how your body processes energy. While lifestyle changes are the first line of defense, pharmaceutical interventions targeting these specific molecular pathways (like kinase inhibitors) are increasingly available and effective for managing conditions like diabetes and fatty liver disease when lifestyle changes are insufficient.

Exogenous administration of spermidine or spermine improves glucose homeostasis, insulin sensitivity, and reduces adiposity in diet-induced obesity mouse models.

Current research indicates that spermidine and spermine supplementation may improve metabolic health in obese individuals, particularly by enhancing insulin sensitivity and reducing fat accumulation. However, most evidence comes from animal models. While human trials show increased blood levels with supplementation, direct metabolic benefits in humans are not yet fully established. Consult a healthcare provider before starting supplementation, especially if you have existing metabolic conditions.

Gut microbiota-derived lipopolysaccharides (LPS) and peptidoglycan (PGN) promote NAFLD progression by activating hepatic Toll-like receptors (TLR4, TLR2, NOD1/2), triggering inflammatory cytokine release and steatosis.

Your liver health is heavily influenced by what lives in your gut. An unhealthy diet can disrupt gut bacteria, allowing harmful bacterial parts (like LPS) to leak into your bloodstream and inflame your liver. Prioritizing a diet that supports a healthy gut microbiome (e.g., high fiber) may help reduce this inflammatory load on the liver.

Gut microbiota-derived metabolites, specifically Short-Chain Fatty Acids (SCFAs) like butyrate, acetate, and propionate, ameliorate NAFLD by inhibiting histone deacetylases (HDACs) and activating G-protein coupled receptors (GPR41, GPR43).

Eating soluble dietary fibers feeds gut bacteria to produce Short-Chain Fatty Acids (SCFAs) like butyrate. These metabolites help reduce liver inflammation and fat accumulation by regulating gene expression and immune responses. Focus on fiber-rich foods rather than isolated SCFA supplements.

Gut microbiota-derived Trimethylamine-N-oxide (TMAO) and secondary bile acids modulate NAFLD progression through regulation of bile acid metabolism, insulin resistance, and hepatic inflammation.

The conversion of dietary nutrients (choline, carnitine) by gut bacteria into TMA, and subsequently TMAO in the liver, influences bile acid metabolism and insulin resistance. Managing dietary intake of these precursors and supporting healthy bile acid signaling (via secondary bile acids) may help manage NAFLD.

Gut microbiota dysbiosis, characterized by elevated pathobionts (e.g., Proteobacteria, Enterobacteriaceae) and depleted beneficial bacteria (e.g., Faecalibacterium, Bifidobacterium), is associated with gestational diabetes mellitus (GDM) and postpartum glucose intolerance, potentially serving as a predictive biomarker for type 2 diabetes.

If you have or had GDM, your gut bacteria may look different from those without GDM, resembling the profile of type 2 diabetes. While this doesn't mean you are doomed, it suggests that maintaining a healthy gut through diet and lifestyle might be a key strategy for preventing type 2 diabetes after pregnancy. Consult your doctor about monitoring your metabolic health.

Gut microbiota dysbiosis in GDM involves elevated lipopolysaccharide (LPS) production and translocation, leading to low-grade inflammation and insulin resistance.

High levels of certain gut bacteria (pathobionts) can lead to inflammation and insulin resistance. While this is a key mechanism in GDM, it is not yet clear if fixing the microbiota alone will cure GDM. Focus on overall metabolic health.

Thyroid dysfunction (both hypo- and hyperthyroidism) is bidirectionally associated with metabolic syndrome components, where thyroid hormones regulate metabolic rate, adiposity, and glucose/lipid metabolism, while adiposity and insulin resistance reciprocally affect thyroid function via leptin and inflammatory cytokines.

If you have metabolic syndrome or obesity, your thyroid health is likely affected, and vice versa. High TSH is associated with higher risk of metabolic syndrome components like high blood pressure, triglycerides, and insulin resistance. Conversely, losing weight and improving insulin sensitivity can improve thyroid function markers. Do not assume treating thyroid levels alone will resolve metabolic issues; address adiposity and insulin resistance concurrently.

Dysregulation of specific microRNAs (miRNAs) in adipose tissue, pancreas, liver, and muscle contributes to the pathogenesis of obesity and related metabolic diseases by altering gene expression involved in energy balance, insulin signaling, and inflammation.

Obesity involves complex biological regulation beyond just calories in vs. calories out. Specific microRNAs in your fat, liver, and muscle cells can become dysregulated, contributing to insulin resistance and inflammation. While lifestyle changes remain foundational, understanding this biological layer explains why obesity can be stubborn and why future treatments may target these specific molecular pathways.

Circulating microRNAs (miRNAs) found in plasma and other body fluids can serve as biomarkers for obesity and metabolic diseases, and may act as endocrine signaling molecules mediating inter-organ communication.

Blood tests may soon be able to detect specific microRNAs that indicate metabolic stress or obesity-related risks before clinical symptoms appear. This could lead to earlier interventions. Additionally, fat tissue may release these molecules to communicate with other organs, influencing metabolism system-wide.

Specific microRNAs (e.g., miR-143, miR-145, miR-27a, miR-130a) regulate adipogenesis (fat cell formation) and insulin sensitivity, with some promoting and others inhibiting fat cell differentiation and glucose homeostasis.

The formation of new fat cells is tightly controlled by specific microRNAs. Some miRNAs encourage fat storage (like miR-143), while others prevent it (like miR-27a). This biological regulation explains why fat distribution and insulin sensitivity vary significantly between individuals.

Gut microbiota alterations in obesity contribute to chronic low-grade inflammation through increased lipopolysaccharide (LPS) translocation, which triggers immune responses and insulin resistance.

High levels of bacterial toxins (LPS) can leak into your bloodstream if your gut barrier is compromised, causing inflammation and insulin resistance. A diet rich in fiber and fermented foods may support gut barrier integrity.